恒瑞医药SHR-4375注射液等6款药品临床试验获批

Core Viewpoint - Heng Rui Medicine announced the approval of multiple clinical trial notifications for new drug candidates by the National Medical Products Administration, indicating a significant advancement in its oncology pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries received approval for clinical trials of SHR-4375 injection, Adebali monoclonal antibody injection, SHR-8068 injection, Bevacizumab injection, HRS-4642 injection, and SHR-9839 for injection [1] - A specific focus is on a multi-center, open-label Phase Ib/II clinical study evaluating the safety, tolerability, and efficacy of SHR-4375 injection in combination with anti-tumor therapy for patients with advanced solid tumors [1]